Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:46 UTC |
---|
HMDB ID | HMDB0014862 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Imiquimod |
---|
Description | Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. miquimod is also used to treat a skin condition of the face and scalp called actinic keratoses and certain types of skin cancer called superficial basal cell carcinoma. |
---|
Structure | CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
---|
Synonyms | Value | Source |
---|
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine | ChEBI | 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline | ChEBI | Imiquimodum | ChEBI | R 837 | ChEBI | Aldara | Kegg | Zyclara | Kegg | Imiquimod acetate | HMDB | 1-Isobutyl-1H-imidazo(4,5-c)quinolin-4-amine | HMDB |
|
---|
Chemical Formula | C14H16N4 |
---|
Average Molecular Weight | 240.3036 |
---|
Monoisotopic Molecular Weight | 240.137496532 |
---|
IUPAC Name | 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine |
---|
Traditional Name | imiquimod |
---|
CAS Registry Number | 99011-02-6 |
---|
SMILES | CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N |
---|
InChI Identifier | InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17) |
---|
InChI Key | DOUYETYNHWVLEO-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as imidazoquinolines. These are aromatic heterocyclic compounds containing an imidazole ring fused to a quinoline ring system. In some configurations, the imidazole ring shares a nitrogen atom with the quinoline moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Quinolines and derivatives |
---|
Sub Class | Imidazoquinolines |
---|
Direct Parent | Imidazoquinolines |
---|
Alternative Parents | |
---|
Substituents | - Imidazoquinoline
- Aminoquinoline
- Imidazopyridine
- Imidazo-[4,5-c]pyridine
- Aminopyridine
- N-substituted imidazole
- Pyridine
- Imidolactam
- Benzenoid
- Azole
- Imidazole
- Heteroaromatic compound
- Azacycle
- Organopnictogen compound
- Hydrocarbon derivative
- Organic nitrogen compound
- Amine
- Organonitrogen compound
- Primary amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 292 - 294 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.25 g/L | Not Available | LogP | 2.7 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Imiquimod,1TMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C)N=C3C=CC=CC3=C21 | 2471.4 | Semi standard non polar | 33892256 | Imiquimod,1TMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C)N=C3C=CC=CC3=C21 | 2310.7 | Standard non polar | 33892256 | Imiquimod,1TMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C)N=C3C=CC=CC3=C21 | 3176.9 | Standard polar | 33892256 | Imiquimod,2TMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=C3C=CC=CC3=C21 | 2434.4 | Semi standard non polar | 33892256 | Imiquimod,2TMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=C3C=CC=CC3=C21 | 2441.4 | Standard non polar | 33892256 | Imiquimod,2TMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=C3C=CC=CC3=C21 | 2838.5 | Standard polar | 33892256 | Imiquimod,1TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 2673.7 | Semi standard non polar | 33892256 | Imiquimod,1TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 2513.9 | Standard non polar | 33892256 | Imiquimod,1TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 3259.7 | Standard polar | 33892256 | Imiquimod,2TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 2823.5 | Semi standard non polar | 33892256 | Imiquimod,2TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 2825.6 | Standard non polar | 33892256 | Imiquimod,2TBDMS,isomer #1 | CC(C)CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=C3C=CC=CC3=C21 | 2992.7 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Imiquimod GC-MS (Non-derivatized) - 70eV, Positive | splash10-0c04-3940000000-1662afa92a44e20e76ba | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Imiquimod GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Imiquimod , positive-QTOF | splash10-000f-2970000000-08cb009f804dd3b43f69 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imiquimod , positive-QTOF | splash10-000i-2910000000-58faefee0903c8967370 | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 10V, Positive-QTOF | splash10-0006-2090000000-6f9d6e2f4d7747ae95db | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 20V, Positive-QTOF | splash10-0a4l-9580000000-d31c7988dbae6085a29d | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 40V, Positive-QTOF | splash10-0a4i-9400000000-503227ffe338b6a8d185 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 10V, Negative-QTOF | splash10-000i-0390000000-44a8c5b2ac2cd485d2f2 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 20V, Negative-QTOF | splash10-001i-0940000000-5f1b9952a672997a0b4e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 40V, Negative-QTOF | splash10-001i-0900000000-d71208eb00e043d7e84f | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 10V, Positive-QTOF | splash10-0006-0390000000-d88591b18aaba14469cd | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 20V, Positive-QTOF | splash10-000f-0690000000-71a9a845a947ea2d2862 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 40V, Positive-QTOF | splash10-05as-0910000000-a9b321d2938173c4f73f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 10V, Negative-QTOF | splash10-000i-0090000000-7474f6fc851ae052786c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 20V, Negative-QTOF | splash10-000i-0090000000-d514bde35ff30a0c785c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imiquimod 40V, Negative-QTOF | splash10-001i-0910000000-946992964c1e54432a88 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14. [PubMed:10411278 ]
- Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22. [PubMed:11812998 ]
- Bilu D, Sauder DN: Imiquimod: modes of action. Br J Dermatol. 2003 Nov;149 Suppl 66:5-8. [PubMed:14616337 ]
- van Egmond S, Hoedemaker C, Sinclair R: Successful treatment of perianal Bowen's disease with imiquimod. Int J Dermatol. 2007 Mar;46(3):318-9. [PubMed:17343595 ]
- 3M [Link]
|
---|